# HJ Science Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hj-science-co

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.hj3h.com/
- Total disclosed funding: $103M
- Latest round: Series C (Jul 11, 2025)
- Investors on record: 14

## About

Based in Chengdu, China, and founded in 2017, HJ Science Co., Ltd. develops therapeutic drug candidates for autoimmune, metabolic, and oncology diseases within the biotechnology industry. The company focuses on small molecule innovative drugs at clinical and preclinical stages. In June 2026, the company raised approximately HKD 1.11 billion in an IPO on the Hong Kong Exchanges and Clearing Ltd (HKEX).

The company develops small molecule drug candidates, including core clinical stage therapies and preclinical pipeline products targeting autoimmune, metabolic, and oncology indications.

The company generates revenue from B2B collaborations and agreements with healthcare institutions and partners related to its therapeutic product development activities.

The company plans to advance clinical research and development of its pipeline products and expand commercialization capabilities as its therapies approach market launch.

## Funding rounds

- Series C, Jul 11, 2025, $9.8M — Fujian Venture, Chengdu Science and Technology Venture Capital Group, Ruihe Xingye Asset
- Series C, Dec 25, 2023, $32M — Chengdu Science and Technology Venture Capital Group, Xingtai Capital, TopAlliance
- Series B, Oct 13, 2021, $6.2M — Sharewin Investment, Xiamen C&D Emerging Industry Equity Investment
- Series B, Oct 13, 2021, $3.1M — Sharewin Investment, Xiamen C&D Emerging Industry Equity Investment
- Series B, Jun 2, 2021, $25M — Shanghai Junshi Biosciences Co., Ltd., Sichuan Venture Capital, Huaige Capital, Ruihe Xingye Asset, Shenghua Chuanghe Investment Management
- Series B, Jun 2, 2021, $4.5M — Huaige Capital, Ruihe Xingye Asset, Shenghua Chuanghe Investment Management
- Series B, Oct 20, 2020, $12M — Legend Capital, Yuanju Capital Asset Management
- Series A, Dec 26, 2017, $10M — SDIC Venture Capital

## Investors

- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- Legend Capital — Series B
- Yuanju Capital Asset Management (https://capitalatlas.ai/funds/yuanju-capital-asset-management) — Series B
- Shanghai Junshi Biosciences Co., Ltd. — Series B
- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Series B
- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series B
- Ruihe Xingye Asset (https://capitalatlas.ai/funds/ruihe-xingye-asset) — Series B, Series C
- Shenghua Chuanghe Investment Management (https://capitalatlas.ai/funds/shenghua-chuanghe-investment-management) — Series B
- Sharewin Investment (https://capitalatlas.ai/funds/sharewin-investment) — Series B
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series B
- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Series C
- Xingtai Capital (https://capitalatlas.ai/funds/xingtai-capital) — Series C
- TopAlliance (https://capitalatlas.ai/funds/topalliance) — Series C
- Fujian Venture (https://capitalatlas.ai/funds/fujian-venture) — Series C